CorMedix (CRMD) Misses Q4 EPS by 7c

CorMedix (NASDAQ: CRMD) reported Q4 EPS of ($0.26), $0.07 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens on INBRX-106 Ph2 Results
• Ipsen names Mariette Finet to its board of directors